Milestone Pharmaceuticals Inc. to Post FY2023 Earnings of $2.89 Per Share, Oppenheimer Forecasts (NASDAQ:MIST)

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) – Stock analysts at Oppenheimer lifted their FY2023 earnings per share estimates for shares of Milestone Pharmaceuticals in a research report issued on Wednesday, November 27th. Oppenheimer analyst L. Gershell now forecasts that the company will post earnings per share of $2.89 for the year, up from their prior forecast of $2.83.

MIST has been the subject of a number of other reports. Cowen reissued a “buy” rating and set a $32.00 target price on shares of Milestone Pharmaceuticals in a research note on Thursday, November 14th. ValuEngine upgraded shares of Milestone Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, October 1st. Finally, Zacks Investment Research lowered shares of Milestone Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 16th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average price target of $30.10.

MIST stock opened at $16.75 on Monday. The firm’s 50-day simple moving average is $18.62 and its 200 day simple moving average is $19.80. Milestone Pharmaceuticals has a fifty-two week low of $15.09 and a fifty-two week high of $27.95.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings results on Wednesday, November 13th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.04).

In other news, major shareholder Rtw Investments, Lp bought 8,150 shares of the company’s stock in a transaction that occurred on Thursday, October 3rd. The shares were purchased at an average price of $17.79 per share, with a total value of $144,988.50. Also, major shareholder Holdings A/S Novo sold 240,000 shares of the business’s stock in a transaction on Monday, November 25th. The stock was sold at an average price of $16.00, for a total value of $3,840,000.00. Following the completion of the sale, the insider now directly owns 2,434,470 shares in the company, valued at approximately $38,951,520. The disclosure for this sale can be found here. Insiders have acquired a total of 513,637 shares of company stock valued at $6,711,967 in the last quarter.

Large investors have recently modified their holdings of the stock. Tower Research Capital LLC TRC acquired a new stake in Milestone Pharmaceuticals during the 2nd quarter worth about $51,000. Millennium Management LLC lifted its position in Milestone Pharmaceuticals by 76.3% in the 3rd quarter. Millennium Management LLC now owns 23,704 shares of the company’s stock worth $410,000 after buying an additional 10,255 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new stake in Milestone Pharmaceuticals in the 2nd quarter worth approximately $459,000. Pentwater Capital Management LP acquired a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter valued at $679,000. Finally, VHCP Management II LLC acquired a new stake in shares of Milestone Pharmaceuticals during the 2nd quarter valued at $4,033,000. Institutional investors and hedge funds own 53.37% of the company’s stock.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

Further Reading: What does the Dogs of the Dow mean?

Earnings History and Estimates for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.